DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0090-9556/04/3205-545-551$20.00
DMD 32:545-551, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, D.
Right arrow Articles by Zhu, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, D.
Right arrow Articles by Zhu, M.

AMIDE N-GLUCURONIDATION OF MAXIPOST CATALYZED BY UDP-GLUCURONOSYLTRANSFERASE 2B7 IN HUMANS

Donglu Zhang, Weiping Zhao, Vikram A. Roongta, James G. Mitroka, Lewis J. Klunk, and Mingshe Zhu

Pharmaceutical Candidate Optimization, Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey

MaxiPost [(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indole-2-one), or BMS-204352)] is a potent and specific maxi-K channel opener for potential use to treat stroke. This article describes structural characterization of a major human N-glucuronide metabolite of BMS-204352 and identification of the enzyme responsible for the N-glucuronidation reaction. After intravenous administrations of [14C]BMS-204352 (10 mg, 50 µCi) to eight healthy human subjects, one major metabolite M representing an average of 17% of the radioactive dose was excreted in pooled urine collected over 0 to 336 h after dosing. A major biliary metabolite of dogs dosed with [14C]BMS-204352 (5 mg/kg), which represented about 33% of the dose, has the same retention time and the same tandem mass spectrometry fragmentation pattern as the human urinary metabolite M. Four hundred fifty micrograms of the metabolite was isolated from the dog bile and analyzed by NMR. Long-range 1H-13C NMR experimentation indicated that the glucuronic acid moiety was at the nitrogen site. The N-glucuronide of BMS-204352 was stable up to 24 h at 37°C in the incubations at different pH values (3.0, 7.4, and 9.0) and with glucuronidases from Escherichia coli and Helix pomatia. Of the seven human UDP-glucuronosyltransferases (UGT) isozymes (1A1, 1A3, 1A4, 1A6, 1A7, 1A10, and 2B7) tested, only UGT2B7 produced metabolite M. UGT2B7-catalyzed N-glucuronidation of BMS-204352 exhibited Michaelis-Menten kinetics with a Km of 14.2 µM and Vmax of 0.29 nmol/min · mg of protein. Collectively, these results suggest that amide N-glucuronidation, a major elimination pathway of MaxiPost, is catalyzed by UGT2B7 in humans. This N-glucuronide represents a fully characterized amide N-glucuronide, and glucuronidation at the nitrogen represents a newly identified conjugation reaction for UGT2B7.


Address correspondence to: Dr. Donglu Zhang, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research Institute, Route 206 and Province-Line Road, Princeton, NJ 08543. E-mail: donglu.zhang{at}bms.com




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
B. Zhu, D. Bush, G. A. Doss, S. Vincent, R. B. Franklin, and S. Xu
Characterization of 1'-Hydroxymidazolam Glucuronidation in Human Liver Microsomes
Drug Metab. Dispos., February 1, 2008; 36(2): 331 - 338.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Kaivosaari, P. Toivonen, L. M. Hesse, M. Koskinen, M. H. Court, and M. Finel
Nicotine Glucuronidation and the Human UDP-Glucuronosyltransferase UGT2B10
Mol. Pharmacol., September 1, 2007; 72(3): 761 - 768.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
L. Xu, D. M. Krenitsky, A. M. Seacat, J. L. Butenhoff, T. R. Tephly, and M. W. Anders
N-GLUCURONIDATION OF PERFLUOROOCTANESULFONAMIDE BY HUMAN, RAT, DOG, AND MONKEY LIVER MICROSOMES AND BY EXPRESSED RAT AND HUMAN UDP-GLUCURONOSYLTRANSFERASES
Drug Metab. Dispos., August 1, 2006; 34(8): 1406 - 1410.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. Rowland, D. J. Elliot, J. A. Williams, P. I. Mackenzie, R. G. Dickinson, and J. O. Miners
IN VITRO CHARACTERIZATION OF LAMOTRIGINE N2-GLUCURONIDATION AND THE LAMOTRIGINE-VALPROIC ACID INTERACTION
Drug Metab. Dispos., June 1, 2006; 34(6): 1055 - 1062.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. Zhang, R. Krishna, L. Wang, J. Zeng, J. Mitroka, R. Dai, N. Narasimhan, R. A. Reeves, N. R. Srinivas, and L. J. Klunk
METABOLISM, PHARMACOKINETICS, AND PROTEIN COVALENT BINDING OF RADIOLABELED MAXIPOST (BMS-204352) IN HUMANS
Drug Metab. Dispos., January 1, 2005; 33(1): 83 - 93.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. G. Staines, M. W. H. Coughtrie, and B. Burchell
N-Glucuronidation of Carbamazepine in Human Tissues Is Mediated by UGT2B7
J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1131 - 1137.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.